Clinical applications of virosomes in cancer immunotherapy

Expert Opinion on Biological Therapy

Volumn 6, Issue 11, 2006, Pages 1113-1121

  Adamina, Michel ^a,b   Guller, Ulrich ^a,b   Bracci, Laura ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a   Schumacher, Reto ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer immunotherapy; Clinical trial; Liposomes; Virosomes

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; HEPATITIS A VACCINE; INFLEXAL; LIPOSOME; TUMOR ANTIGEN; VIROSOME VACCINE;

ANTIGEN DETECTION; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG FORMULATION; DRUG MECHANISM; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPOTENTIATION; KAPOSI SARCOMA; MELANOMA; NONHUMAN; REVIEW; VIRUS ENVELOPE;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; VIRAL VACCINES; VIROSOMES;

EID: 33750797203     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.11.1113     Document Type: Review

References (69)

1. COLEY WB: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am. J. Med. Sci. (1893) 105:487-511.
2. ADAMINA M, OERTLI D: Antigen specific active immunotherapy: lessons from the first decade. Swiss Med. Wkly (2005) 135(15-16):212-221.
3. BUZAID AC: Management of metastatic cutaneous melanoma. Oncology (Williston Park) (2004) 18(11):1443-1450.
4. VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647.
5. NOVELLINO L, CASTELLI C, PARMIANI G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. (2005) 54(3):187-207.
6. DUNN GP, BRUCE AT, IKEDA H, OLD LJ, SCHREIBER RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. (2002) 3(11):991-998.
7. LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. (1996) 14:233-258.
8. ZAJAC P, OERTLI D, MARTI W et al.: Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther. (2003) 14(16):1497-1510. A Phase I/II immunotherapy trial in melanoma patients that shows the need for advanced epitope carriers and strong adjuvants in clinical immunotherapy.
9. FEDER-MENGUS C, SCHULTZ-THATER E, OERTLI D et al.: Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Hum. Gene Ther. (2005) 16(3):348-360.
10. RAMMENSEE HG, FALK K, ROTZSCHKE O: Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. (1993) 11:213-244.
11. ALBO F, CAVAZZA A, GIARDINA B et al.: Degradation of the tumor antigen epitope gp100(280-288) by fibroblast-associated enzymes abolishes specific immunorecognition. Biochim. Biophys. Acta (2004) 1671(1-3):59-69.
12. BLANCHET JS, VALMORI D, DUFAU I et al.: A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J. Immunol. (2001) 167(10):5852-5861.
13. CAVAZZA A, ADAMINA M, AUSIELLO CM et al.: Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin. Immunol. (2004) 111(3):252-261.
14. AMOSCATO AA, PRENOVITZ DA, LOTZE MT: Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. (1998) 161(8):4023-4032.
15. ADAMINA M, BOLLI M, ALBO F et al.: Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Br. J. Cancer (2004) 90(1):263-269. A paper showing the protection and adjuvant capacity of synthetic, sterically stabilised liposomes in the induction of melanoma-specific CTL responses.
16. 280-288. ChemMedChem (2006) 1(8):816-820.
17. SCHUMACHER R, AMACKER M, NEUHAUS D et al.: Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1 (26-35) peptide encapsulated into virosomes in vitro. Vaccine (2005) 23(48-49):5572-5582. Demonstration of the high epitope encapsulation capacity, inherent adjuvant profile and delivery features of chimeric immunopotentiating reconstituted influenza virosomes in melanoma immunotherapy, as a reagent scheduled to enter a melanoma immunotherapy trial in the near future.
18. HODGE JW, GROSENBACH DW, SCHLOM J: Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect. Prev. (2002) 26(4):275-291.
19. ADAMINA M, DAETWILER S, ROSENTHAL R, ZAJAC P: Clinical applications of recombinant virus-based cancer immunotherapy. Expert Opin. Biol. Ther. (2005) 5(9):1211-1224. An exhaustive and recent review on recombinant virus-based cancer immunotherapy as one of the most powerful existing approaches to tumour vaccination.
20. VAN BAREN N, BONNET MC, DRENO B et al.: Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. (2005) 23(351:9008-9021.
21. OERTLI D, MARTI WR, ZAJAC P et al.: Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum. Gene Ther. (2002) 13(4):569-575.
22. HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. (2000) 49(9):504-514.
23. ROSENBERG SA, ZHAI Y, YANG JC et al.: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. (1998) 90(24):1894-1900.
24. SCHNEIDER J, GILBERT SC, HANNAN CM et al.: Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. (1999) 170:29-38.
25. ALMEIDA JD, EDWARDS DC, BRAND CM, HEATH TD: Formation of virosomes from influenza subunits and liposomes. Lancet (1975) 2(7941):899-901.
26. AGRAWAL B, KRANTZ MJ, REDDISH MA, LONGENECKER BM: Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int. Immunol. (1998) 10(12):1907-1916.
27. ADAMINA M, SCHUMACHER R, ZAJAC P et al.: Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy. J. Liposome Res. (2006) 16(3):195-204.
28. SENIOR J, CRAWLEY JC, GREGORIADIS G: Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim. Biophys. Acta (1985) 839(1):1-8.
29. OUSSOREN C, STORM G: Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. (2001) 50(1-2):143-156.
30. IGNATIUS R, MAHNKE K, RIVERA M et al.: Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood (2000) 96(10):3505-3513.
31. SCHOEN P, CHONN A, CULLIS PR, WlLSCHUT J, SCHERRER P: Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther. (1999) 6(5):823-832.
32. WAELTI ER, GLUCK R: Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer (1998) 77(5):728-733.
33. GLUCK R, METCALFE IC: Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine (2003) 21(7-8):611-615.
34. GLUCK R, MOSER C, METCALFE IC: Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther. (2004) 4(7):1139-1145. A recent general review developing the broad versatility of immunopotentiating reconstituted influenza virosomes in vaccinology.
35. ZURBRIGGEN R: Immunostimulating reconstituted influenza virosomes. Vaccine (2003) 21(9-10):921-924.
36. PECTASIDES D, PSYRRI A, PECTASIDES M, ECONOMOPOULOS T: Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin. Pharmacother. (2006) 7(8):975-987.
37. SHARPE M, EASTHOPE SE, KEATING GM, LAMB HM: Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AlDS-related Kaposi's sarcoma. Drugs (2002) 62(14):2089-2126.
38. GlBBS WJ, DREW RH, PERFECT JR: Liposomal amphotericin B: clinical experience and perspectives. Expert Rev. Anti Infect. Ther. (2005) 3(2):167-181.
39. ARKEMA A, HUCKRIEDE A, SCHOEN P, WlLSCHUT J, DAEMEN T: Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine (2000) 18(14):1327-1333.
40. BAGAI S, SARKAR DP: Effect of substitution of hemagglutinin-neuraminidase with influenza hemagglutinin on Sendai virus F protein mediated membrane fusion. FEBS Lett. (1994) 353(3):332-336.
41. BAGAI S, SARKAR DP: Reconstituted Sendai virus envelopes as biological carriers: dual role of F protein in binding and fusion with liver cells. Biochim. Biophys. Acta (1993) 1152(1):15-25.
42. NAKANISHI T, HAYASHI A, KUNISAWA J et al.: Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. (2000) 30(6):1740-1747.
43. GREENSTONE HL, NIELAND JD, DE VISSER KE et al.: Chimeric papillomavirus virus-like particles elicit ami tumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA (1998) 95(4):1800-1805.
44. SCHAFER K, MULLER M, FAATH S et al.: Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer (1999) 81(6):881-888.
45. SEDLIK C, SARON M, SARRASECA J, CASAL I, LECLERC C: Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. USA (1997) 94(14):7503-7508.
46. SCHIRMBECK R, DEML L, MELBER K, WOLF H, WAGNER R, REIMANN J: Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine (1995) 13(9):857-865.
47. STORNI T, RUEDL C, SCHWARZ K, SCHWENDENER RA, RENNER WA, BACHMANN MF: Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. (2004) 172(3):1777-1785.
48. NEIDHART J, ALLEN KO, BARLOW DL et al.: Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine (2004) 22(5-6):773-780.
49. GRIMALDI S, GIULIANI A, GIULIANI A et al.: Engineered liposomes and virosomes for delivery of macromolecules. Res. Virol. (1995) 146(4):289-293.
50. ORELLANA A, MOTTERSHEAD D, VAN DER LINDEN I, KEINANEN K, OKER-BLOM C: Mimicking rubella virus particles by using recombinant envelope glycoproteins and liposomes. J. Biotechnol. (1999) 75(2-3):209-219.
51. SHOJI J, TANIHARA Y, UCHIYAMA T, KAWAI A: Preparation of virosomes coated with the vesicular stomatitis virus glycoprotein as efficient gene transfer vehicles for animal cells. Microbiol Immunol. (2004) 48(3):163-174.
52. REN H, BOULIKAS T, LUNDSTROM K, SOLING A, WARNKE PC, RAINOV NG: Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a Phase I/II clinical protocol. J. Neurooncol. (2003) 64(1-2):147-154.
53. LEVCHENKO TS, RAMMOHAN R, VOLODlNA N, TORCHILIN VP: Tat peptide-mediated intracellular delivery of liposomes. Methods Enzymol. (2003) 372:339-349.
54. KAPCZYNSKI DR, TUMPEY TM: Development of a virosome vaccine for Newcastle disease virus. Avian Dis. (2003) 47(3):578-587.
55. ELLIOTT G, O'HARE P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell (1997) 88(2):223-233.
56. DAEMEN T, DE MARE A, BUNGENER L, DE JONGE J, HUCKRIEDE A, WILSCHUT J: Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev. (2005) 57(3):451-463. A recent and exhaustive review on the antigen and DNA delivery capacities of influenza virosomes.
57. BUNGENER L, SERRE K, BIJL L et al.: Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine (2002) 20(17-18):2287-2295.
58. SCHUMACHER R, ADAMINA M, ZURBRIGGEN R et al.: Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine (2004) 22(5-6):714-723. Demonstration of the intrinsic high adjuvant capacity of immunopotentiating reconstituted influenza virosomes.
59. SCHWANINGER R, WAELTI E, ZAJAC P, WETTERWALD A, MUELLER D, GIMMI CD: Virosomes as new carrier system for cancer vaccines. Cancer Immunol. Immunother. (2004) 53(10):1005-1017. A further demonstration of the adjuvant and carrier properties of immunopotentiating reconstituted influenza virosomes in the context of breast cancer immunotherapy.
60. BUNGENER L, HUCKRIEDE A, DE MARE A, VRIES-IDEMA J, WILSCHUT J, DAEMEN T: Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine (2005) 23(10):1232-1241. A demonstration of the in vivo delivery capacity of influenza virosomes within a mouse model.
61. SALLUSTO F, KREMMER E, PALERMO B et al.: Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur. J. Immunol. (1999) 29(6):2037-2045.
62. AMACKER M, ENGLER O, KAMMER AR et al.: Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol. (2005) 17(6):695-704. Demonstration of the adjuvant and delivery capacities of immunopotentiating reconstituted influenza virosomes within a mouse model of hepatitis C, that is, the potential of an immunotherapeutic approach against a chronic infectious disease.
63. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. (2003) 9(8):2973-2980.
64. WEBER J, SONDAK VK, SCOTLAND R et al.: Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 97(1):186-200.
65. DURRER P, GLUCK U, SPYR C et al.: Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine (2003) 21(27-30):4328-4334.
66. http://www.who.int/whr/2004/annex/topic/en/annex_2_en.pdf WHO: WHO mortality database (2004).
67. http://seer.cancer.gov/csr/1975_2003 RIES LAG, HARKINS D, KRAPCHO M et al.: SEER Cancer Statistics Review, 1975-2003. National Cancer Institute, Bethesda, MD, USA (2006).
68. http://www.un.org/esa/population/publications/worldageing19502050/ United Nations, Department of Economic and Social Affairs, Population Division: World Population Ageing: 1950-2050 (2006).
69. http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm VAN DEN EYNDE B, STROOBANT V, VAN PEL A, VAN DER BRUGGEN B: T-cell defined tumor antigens. Cancer Immunity (2006).